179 related articles for article (PubMed ID: 37518874)
21. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
Ueda T; Uemura H; Tomita Y; Tsukamoto T; Kanayama H; Shinohara N; Tarazi J; Chen C; Kim S; Ozono S; Naito S; Akaza H
Jpn J Clin Oncol; 2013 Jun; 43(6):616-28. PubMed ID: 23630366
[TBL] [Abstract][Full Text] [Related]
22. Axitinib: in advanced, treatment-experienced renal cell carcinoma.
Yang LP; McKeage K
Drugs; 2012 Dec; 72(18):2375-84. PubMed ID: 23190347
[TBL] [Abstract][Full Text] [Related]
23. Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
Meza L; McDermott DF; Escudier B; Hutson TE; Porta C; Verzoni E; Atkins MB; Kasturi V; Pal SK; Rini B
Oncologist; 2023 Mar; 28(3):e167-e170. PubMed ID: 36576430
[TBL] [Abstract][Full Text] [Related]
24. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
25. Axitinib modulates hypoxia-induced blood-retina barrier permeability and expression of growth factors.
Kernt M; Thiele S; Liegl RG; Kernt B; Eibl K; Haritoglou C; Ulbig MW; Kampik A
Growth Factors; 2012 Feb; 30(1):49-61. PubMed ID: 22168366
[TBL] [Abstract][Full Text] [Related]
26. Differentiation of glioblastoma stem cells promoted by miR-128 or miR-302a overexpression enhances senescence-associated cytotoxicity of axitinib.
Cardoso AM; Morais CM; Pena F; Marante T; Cunha PP; Jurado AS; Pedroso de Lima MC
Hum Mol Genet; 2021 Apr; 30(3-4):160-171. PubMed ID: 33438013
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.
Duerinck J; Du Four S; Vandervorst F; D'Haene N; Le Mercier M; Michotte A; Van Binst AM; Everaert H; Salmon I; Bouttens F; Verschaeve V; Neyns B
J Neurooncol; 2016 May; 128(1):147-155. PubMed ID: 26935577
[TBL] [Abstract][Full Text] [Related]
28. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.
Rini BI; Quinn DI; Baum M; Wood LS; Tarazi J; Rosbrook B; Arruda LS; Cisar L; Roberts WG; Kim S; Motzer RJ
Target Oncol; 2015 Mar; 10(1):45-53. PubMed ID: 24595903
[TBL] [Abstract][Full Text] [Related]
29. The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.
Tzogani K; Skibeli V; Westgaard I; Dalhus M; Thoresen H; Slot KB; Damkier P; Hofland K; Borregaard J; Ersbøll J; Salmonson T; Pieters R; Sylvester R; Mickisch G; Bergh J; Pignatti F
Oncologist; 2015 Feb; 20(2):196-201. PubMed ID: 25616431
[TBL] [Abstract][Full Text] [Related]
30. Glioblastoma Cells Do Not Affect Axitinib-Dependent Senescence of HUVECs in a Transwell Coculture Model.
Merolle M; Mongiardi MP; Piras M; Levi A; Falchetti ML
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098270
[TBL] [Abstract][Full Text] [Related]
31. Axitinib for the treatment of advanced renal cell carcinoma.
Akaza H; Fukuyama T
Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
[TBL] [Abstract][Full Text] [Related]
32. Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo.
He Q; Gao J; Ge S; Wang T; Li Y; Peng Z; Li Y; Shen L
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1575-83. PubMed ID: 24804814
[TBL] [Abstract][Full Text] [Related]
33. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Cohen EE; Rosen LS; Vokes EE; Kies MS; Forastiere AA; Worden FP; Kane MA; Sherman E; Kim S; Bycott P; Tortorici M; Shalinsky DR; Liau KF; Cohen RB
J Clin Oncol; 2008 Oct; 26(29):4708-13. PubMed ID: 18541897
[TBL] [Abstract][Full Text] [Related]
34. Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets.
MacLean E; Cisar L; Mehle K; Eremina D; Quigley JM
J Manag Care Spec Pharm; 2016 Jun; 22(6):723-732u. PubMed ID: 27231799
[TBL] [Abstract][Full Text] [Related]
35. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
[TBL] [Abstract][Full Text] [Related]
36. Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.
Lee N; Lee JL; Lee JY
Target Oncol; 2023 Mar; 18(2):247-255. PubMed ID: 36826462
[TBL] [Abstract][Full Text] [Related]
37. Axitinib-Loaded Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Age-Related Macular Degeneration: Formulation Development and
Narvekar P; Bhatt P; Fnu G; Sutariya V
Assay Drug Dev Technol; 2019; 17(4):167-177. PubMed ID: 31184962
[No Abstract] [Full Text] [Related]
38. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
Bhatta SS; Wroblewski KE; Agarwal KL; Sit L; Cohen EE; Seiwert TY; Karrison T; Bakris GL; Ratain MJ; Vokes EE; Maitland ML
Oncologist; 2013; 18(8):965-70. PubMed ID: 23900000
[TBL] [Abstract][Full Text] [Related]
39. The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.
Rössler J; Monnet Y; Farace F; Opolon P; Daudigeos-Dubus E; Bourredjem A; Vassal G; Geoerger B
Int J Cancer; 2011 Jun; 128(11):2748-58. PubMed ID: 20715103
[TBL] [Abstract][Full Text] [Related]
40. Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.
Stehle F; Schulz K; Fahldieck C; Kalich J; Lichtenfels R; Riemann D; Seliger B
J Biol Chem; 2013 Jun; 288(23):16334-16347. PubMed ID: 23625925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]